Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Tyrosine kinase inhibitors Stories

2009-12-05 10:00:00

Omacetaxine launches different attack on CML that is impervious to other therapies NEW ORLEANS "• Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology. The injectable drug omacetaxine achieved durable responses in some...

2009-12-02 17:45:00

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Kinase Inhibitors: Global Markets http://www.reportlinker.com/p0166819/Kinase-Inhibitors-Global-Markets.html Forecasts for the global market, providing data for the years 2005 through 2008, and projections for the market and compound annual growth rates (CAGRs) through 2014 An overview of the market for the kinase inhibitor class of drugs that already are...

2009-12-01 06:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that eleven presentations on preclinical studies of the company's product candidates will be given at the upcoming American Society of Hematology (ASH) Meeting and Exposition in New Orleans, Louisiana from December 5-8, 2009. Rigel's R788, an oral Syk kinase inhibitor, will be discussed in two oral presentations by collaborators about its activity in distinct B-cell...

2009-10-20 00:15:00

EAST HANOVER, N.J., Oct. 20 /PRNewswire/ -- Novartis announced today that Tasigna® (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec® (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)...

2009-10-08 11:07:23

UH Case Medical Center study in JCO reinforces focus on personalized treatment for patients based on ethnicity Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs. Published online in the Journal of Clinical Oncology, the study by Rom Leidner, MD, and colleagues report that ethnicity plays a...

2009-09-30 11:01:23

In new research published in the open-access, peer-reviewed scientific journal PLoS ONE, Dr Patrice Dubreuil and colleagues characterize the pharmacological profile of masitinib (AB1010), a novel tyrosine kinase inhibitor (TKI) that targets the stem cell factor (KIT), PDGFR and Lyn. Masitinib is the active pharmacological ingredient of the first ever registered veterinary anticancer drug, Masivet® (1). The main cellular targets of masitinib are mast cells, meaning this drug...

2009-09-29 07:00:00

NEW YORK, Sept. 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced updated clinical results from a Phase 2 study of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single-agent treatment for advanced metastatic renal cell carcinoma (RCC). Dr. Thomas E. Hutson, Director of the Genitourinary Oncology Program at Baylor-Sammons Cancer Center in Dallas, Texas, presented the data on Saturday, September 26th, in an oral...

2009-09-14 07:30:00

NEW YORK, Sept. 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009. Dr. Thomas E. Hutson, Director of the Genitourinary Oncology Program...

2009-09-14 07:00:00

WALTHAM, Mass., Sept.14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class. The new Pharmacor...

2009-09-10 07:46:00

NEW YORK, Sept. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. World Cancer Therapies Market http://www.reportlinker.com/p0109886/World-Cancer-Therapies-Market.html This report analyzes the global market for Cancer Therapies in US$ Billion. The specific product segments analyzed are Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immunotherapy. Annual forecasts for the global market is provided for the period of 2006...